AbbVie Stock Will Hit $300 on This Date

The post AbbVie Stock Will Hit $300 on This Date appeared first on 24/7 Wall St..

AbbVie (NYSE:ABBV) has quietly become one of healthcare’s most underrated growth stories. CEO Robert A. Michael told investors after Q1, “We are off to an excellent start in 2026, with first-quarter results exceeding our expectations.”

The numbers back him up. Immunology revenue hit $7.29 billion, with Skyrizi up 30.9% and Rinvoq up 23.3%. Yet shares trade at just $221.59, down 1.43% YTD. Can AbbVie hit $300 by 2030?

What’s Holding AbbVie Back Right Now

The disconnect is real. Shares are off 0.66% over the past week despite revenue accelerating to +12.4% YoY in Q1 2026.

Net income fell 45.96% YoY, largely due to a $744 million acquired in-process R&D charge that clipped EPS by $0.41. The market treats those charges as recurring damage rather than pipeline investment.

Add the structural Humira biosimilar decline (revenue fell 38.6% to $688 million) and Imbruvica’s 24.7% decline, and you have a stock investors keep underwriting at a discount. With a beta of just 0.309, this trades as a low-volatility defensive name.

Wall Street Sees 14% Upside. I Think That’s Too Cautious

The consensus target is $253.55, implying roughly 14.4% upside. Ratings split: 8 Strong Buy, 16 Buy, 8 Hold, zero sells. Our base case 247Factor model lands at $245.35 (10.72% upside), with an optimistic case at $258.62 and a bear case of $219.27. Confidence on the base case is 90%.

Bullish sentiment sits at 75%, yet earnings growth gets penalized because of IPR&D noise. Strip those charges, and management already raised full-year guidance to $14.08 to $14.28. Analysts and our model anchor on a one-year window. $300 is a multi-year question.

The Path to $300 Per Share

Reaching $300 from today’s price of $221.59 requires a gain of 35.4%. With forward EPS of $12.78, a price of $300 implies a forward P/E of 23x. Our base case of $245.35 already implies 22x, meaning the bold target requires only about 2x additional multiple expansion.

The adjustment factor in our model is 1.103, lifted by healthcare sector momentum and 75% bullish analyst consensus, but capped by mega-cap dampening.

Skyrizi crossed $5.01 billion last quarter and is still growing 30%+. Qulipta is up 53.6%. Michael told investors, “Our pipeline progress and solid business fundamentals position AbbVie for robust long-term growth.” Our 5-year bull case models $301 by June 2030. The primary risk is faster-than-expected erosion across the legacy oncology franchise.

Where AbbVie Trades Today vs Its Earnings Power

At $221.59 against forward EPS of $12.78, ABBV trades at a forward P/E of 17x. That looks cheap for a business growing top-line at +12.4% with operating margins above 32%.

Shares sit between a 52-week range of $176 and $239.13, currently about 6% off the high. ABBV has returned 457.85% over 10 years and 131.55% over five. A 35% climb to $300 over roughly four years is well within that historical pace.

Is $300 Realistic? Here’s My Take

Reaching $300 requires a 35.4% gain, realistic on a multi-year timeline rather than a 12-month sprint.

Three things need to go right: Skyrizi and Rinvoq need to keep compounding at 20%+, IPR&D charge noise must fade so reported EPS converges with adjusted EPS, and the neuroscience franchise needs to sustain its +26% growth trajectory. A faster collapse in Humira and Imbruvica revenue than next-gen drugs can absorb would derail it. We’ve outlined the blueprint for how AbbVie could reach $300 in 2030.

The post AbbVie Stock Will Hit $300 on This Date appeared first on 24/7 Wall St..